VLP-Based Vaccines as a Suitable Technology to Target Trypanosomatid Diseases

Research on vaccines against trypanosomatids, a family of protozoa that cause neglected tropical diseases, such as Chagas disease, leishmaniasis, and sleeping sickness, is a current need. Today, according to modern vaccinology, virus-like particle (VLP) technology is involved in many vaccines, inclu...

Full description

Saved in:

Bibliographic Details
Published in:	Vaccines (Basel) Vol. 9; no. 3; p. 220
Main Authors:	Queiroz, Aline Maria Vasconcelos, Oliveira, Johny Wysllas de Freitas, Moreno, Cláudia Jassica, Guérin, Diego M A, Silva, Marcelo Sousa
Format:	Journal Article
Language:	English
Published:	Switzerland MDPI AG 05-03-2021 MDPI
Subjects:	Adjuvants African trypanosomiasis Antigens Chagas disease Context COVID-19 Cytokines Development strategies Gene expression Human papillomavirus Immune system Immunostimulation Infections Infectious diseases Leishmaniasis Parasites Parasitic diseases Protozoa Review Tropical diseases trypanosomatids Tumor necrosis factor-TNF vaccine Vaccines Vector-borne diseases Viral infections Virulence Virus-like particles Viruses trypanosomatids Chagas disease virus-like particles vaccine leishmaniasis African trypanosomiasis
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Abstract	Research on vaccines against trypanosomatids, a family of protozoa that cause neglected tropical diseases, such as Chagas disease, leishmaniasis, and sleeping sickness, is a current need. Today, according to modern vaccinology, virus-like particle (VLP) technology is involved in many vaccines, including those undergoing studies related to COVID-19. The potential use of VLPs as vaccine adjuvants opens an opportunity for the use of protozoan antigens for the development of vaccines against diseases caused by , spp., and . In this context, it is important to consider the evasion mechanisms of these protozoa in the host and the antigens involved in the mechanisms of the parasite-host interaction. Thus, the immunostimulatory properties of VLPs can be part of an important strategy for the development and evaluation of new vaccines. This work aims to highlight the potential of VLPs as vaccine adjuvants for the development of immunity in complex diseases, specifically in the context of tropical diseases caused by trypanosomatids.
AbstractList	Research on vaccines against trypanosomatids, a family of protozoa that cause neglected tropical diseases, such as Chagas disease, leishmaniasis, and sleeping sickness, is a current need. Today, according to modern vaccinology, virus-like particle (VLP) technology is involved in many vaccines, including those undergoing studies related to COVID-19. The potential use of VLPs as vaccine adjuvants opens an opportunity for the use of protozoan antigens for the development of vaccines against diseases caused by , spp., and . In this context, it is important to consider the evasion mechanisms of these protozoa in the host and the antigens involved in the mechanisms of the parasite-host interaction. Thus, the immunostimulatory properties of VLPs can be part of an important strategy for the development and evaluation of new vaccines. This work aims to highlight the potential of VLPs as vaccine adjuvants for the development of immunity in complex diseases, specifically in the context of tropical diseases caused by trypanosomatids. Research on vaccines against trypanosomatids, a family of protozoa that cause neglected tropical diseases, such as Chagas disease, leishmaniasis, and sleeping sickness, is a current need. Today, according to modern vaccinology, virus-like particle (VLP) technology is involved in many vaccines, including those undergoing studies related to COVID-19. The potential use of VLPs as vaccine adjuvants opens an opportunity for the use of protozoan antigens for the development of vaccines against diseases caused by Trypanosoma cruzi, Leishmania spp., and Trypanosoma brucei. In this context, it is important to consider the evasion mechanisms of these protozoa in the host and the antigens involved in the mechanisms of the parasite–host interaction. Thus, the immunostimulatory properties of VLPs can be part of an important strategy for the development and evaluation of new vaccines. This work aims to highlight the potential of VLPs as vaccine adjuvants for the development of immunity in complex diseases, specifically in the context of tropical diseases caused by trypanosomatids. Research on vaccines against trypanosomatids, a family of protozoa that cause neglected tropical diseases, such as Chagas disease, leishmaniasis, and sleeping sickness, is a current need. Today, according to modern vaccinology, virus-like particle (VLP) technology is involved in many vaccines, including those undergoing studies related to COVID-19. The potential use of VLPs as vaccine adjuvants opens an opportunity for the use of protozoan antigens for the development of vaccines against diseases caused by Trypanosoma cruzi , Leishmania spp., and Trypanosoma brucei . In this context, it is important to consider the evasion mechanisms of these protozoa in the host and the antigens involved in the mechanisms of the parasite–host interaction. Thus, the immunostimulatory properties of VLPs can be part of an important strategy for the development and evaluation of new vaccines. This work aims to highlight the potential of VLPs as vaccine adjuvants for the development of immunity in complex diseases, specifically in the context of tropical diseases caused by trypanosomatids.
Author	Silva, Marcelo Sousa Oliveira, Johny Wysllas de Freitas Moreno, Cláudia Jassica Guérin, Diego M A Queiroz, Aline Maria Vasconcelos
AuthorAffiliation	1 Immunoparasitology Laboratory, Department of Clinical and Toxicological Analysis, Federal University of Rio Grande do Norte, Natal 59078-970, Brazil; alinemariavq@gmail.com (A.M.V.Q.); johny3355@hotmail.com (J.W.d.F.O.); claudia.mrn1@gmail.com (C.J.M.) 2 Postgraduate Program in Pharmaceutical Sciences, Federal University of Rio Grande do Norte, Natal 59078-970, Brazil 4 Instituto Biofisika (CSIC-UPV/EHU), Department of Biochemistry and Molecular Biology, University of the Basque Country, 48940 Bizkaia, Spain 3 Postgraduate Program in Biochemistry, Federal University of Rio Grande do Norte, Natal 59078-970, Brazil 5 Global Health and Tropical Medicine, Institute of Hygiene and Tropical Medicine, New University of Lisbon, 1349-008 Lisbon, Portugal
AuthorAffiliation_xml	– name: 1 Immunoparasitology Laboratory, Department of Clinical and Toxicological Analysis, Federal University of Rio Grande do Norte, Natal 59078-970, Brazil; alinemariavq@gmail.com (A.M.V.Q.); johny3355@hotmail.com (J.W.d.F.O.); claudia.mrn1@gmail.com (C.J.M.) – name: 4 Instituto Biofisika (CSIC-UPV/EHU), Department of Biochemistry and Molecular Biology, University of the Basque Country, 48940 Bizkaia, Spain – name: 5 Global Health and Tropical Medicine, Institute of Hygiene and Tropical Medicine, New University of Lisbon, 1349-008 Lisbon, Portugal – name: 3 Postgraduate Program in Biochemistry, Federal University of Rio Grande do Norte, Natal 59078-970, Brazil – name: 2 Postgraduate Program in Pharmaceutical Sciences, Federal University of Rio Grande do Norte, Natal 59078-970, Brazil
Author_xml	– sequence: 1 givenname: Aline Maria Vasconcelos orcidid: 0000-0002-1811-7376 surname: Queiroz fullname: Queiroz, Aline Maria Vasconcelos organization: Postgraduate Program in Pharmaceutical Sciences, Federal University of Rio Grande do Norte, Natal 59078-970, Brazil – sequence: 2 givenname: Johny Wysllas de Freitas orcidid: 0000-0002-3100-0420 surname: Oliveira fullname: Oliveira, Johny Wysllas de Freitas organization: Postgraduate Program in Biochemistry, Federal University of Rio Grande do Norte, Natal 59078-970, Brazil – sequence: 3 givenname: Cláudia Jassica orcidid: 0000-0002-6948-9823 surname: Moreno fullname: Moreno, Cláudia Jassica organization: Postgraduate Program in Biochemistry, Federal University of Rio Grande do Norte, Natal 59078-970, Brazil – sequence: 4 givenname: Diego M A orcidid: 0000-0001-8504-9636 surname: Guérin fullname: Guérin, Diego M A organization: Instituto Biofisika (CSIC-UPV/EHU), Department of Biochemistry and Molecular Biology, University of the Basque Country, 48940 Bizkaia, Spain – sequence: 5 givenname: Marcelo Sousa orcidid: 0000-0002-1000-0149 surname: Silva fullname: Silva, Marcelo Sousa organization: Global Health and Tropical Medicine, Institute of Hygiene and Tropical Medicine, New University of Lisbon, 1349-008 Lisbon, Portugal
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/33807516$$D View this record in MEDLINE/PubMed
BookMark	eNpdkdtrHCEUxqUkNJfmuW9loC99mUQ9Oo4vhTa9JLClhW5D38TxsnGZHTc6E9j_Pia7CUlEVI7f-X1HzxHaG-LgEHpP8CmAxGe32pgwuCwxYErxG3RIsWhqkPB_79n5AJ3kvMRlSAJtI96iA4AWC06aQ_Travan_qqzs9XVDlfpMqu_Uxh117tq7sz1EPu42FRjrOY6LdxYzdNmrYeY40qPwVbfQnaFkd-hfa_77E52-zH69-P7_Pyinv3-eXn-ZVYb1oqxBucl1sRAQy0DClx6kIRxwyxY5jpcwr4jwjJOOw-N8AyXRWNiJbe-hWN0ueXaqJdqncJKp42KOqiHQEwLpdMYTO-UoYBN8QHKPWOd6XxxK_bMcuw5QGF93rLWU7dy1rhhTLp_AX15M4RrtYi3SkjZCo4L4NMOkOLN5PKoViEb1_d6cHHKinLcctGw9r7uj6-kyziloXyVokxKIIQ8VHS2VZkUc07OPxVDsLrvvHrV-ZLx4fkbnvSPfYY7eB6sTw
CitedBy_id	crossref_primary_10_3390_vaccines12030271 crossref_primary_10_1155_2021_7809637 crossref_primary_10_1002_mco2_228 crossref_primary_10_1002_ps_7514
Cites_doi	10.1038/s41598-019-41522-5 10.3390/biomedicines8040091 10.1188/06.CJON.559-560 10.3390/vaccines8010130 10.1016/j.actatropica.2019.105168 10.3390/vaccines8010139 10.1007/s12033-012-9598-4 10.1007/978-1-4939-3618-2_27 10.1586/14760584.6.3.381 10.4049/jimmunol.178.4.2361 10.1016/S0264-410X(01)00518-7 10.1016/j.tim.2010.11.003 10.3390/v12030270 10.21608/puj.2019.20020.1055 10.3390/pathogens8040178 10.1007/s12275-017-7058-3 10.1007/s00415-019-09425-7 10.1016/S0140-6736(18)31204-2 10.18388/abp.2014_1875 10.1016/j.addr.2014.10.023 10.1016/j.vaccine.2019.04.042 10.1016/j.pt.2017.10.001 10.1016/j.molimm.2004.06.028 10.3389/fimmu.2017.00226 10.1371/journal.pntd.0005951 10.1002/eji.201847917 10.1016/j.vetimm.2012.04.026 10.1111/pim.12387 10.1586/14760584.3.2.119 10.1016/j.bbadis.2019.165658 10.1016/j.vaccine.2020.05.010 10.1016/j.ymeth.2006.07.018 10.1016/j.vaccine.2016.03.074 10.1016/S0140-6736(07)60946-5 10.1371/journal.pntd.0005608 10.1016/j.vaccine.2018.08.016 10.1007/s00253-015-7000-8 10.1039/D0MD00122H 10.1016/j.vaccine.2008.07.002 10.1016/j.vaccine.2011.05.005 10.2174/1389202033490439 10.1007/978-1-4419-1132-2_11 10.1016/j.vaccine.2019.09.068 10.1590/s1678-9946201759046 10.1186/s12985-018-0970-2 10.1016/j.vaccine.2018.08.033 10.2147/ITT.S241064 10.1021/acscentsci.7b00311 10.2147/DDDT.S146521 10.3390/v12010035 10.1016/j.protis.2017.03.004 10.1002/biot.201400427 10.1016/j.coviro.2016.03.001 10.1016/S0140-6736(17)31612-4 10.1016/j.molbiopara.2016.03.007 10.1038/s41467-018-08265-9 10.1371/journal.pone.0216533 10.1002/jps.22267 10.33073/pjm-2015-001 10.1038/s41598-019-53208-z 10.1093/molbev/msp214 10.1128/JVI.01884-19
ContentType	Journal Article
Copyright	2021. This work is licensed under http://creativecommons.org/licenses/by/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. 2021 by the authors. 2021
Copyright_xml	– notice: 2021. This work is licensed under http://creativecommons.org/licenses/by/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: 2021 by the authors. 2021
DBID	NPM AAYXX CITATION 3V. 7T7 7XB 8FD 8FE 8FH 8FK 8G5 ABUWG AFKRA AZQEC BBNVY BENPR BHPHI C1K CCPQU COVID DWQXO FR3 GNUQQ GUQSH HCIFZ LK8 M2O M7P MBDVC P64 PIMPY PQEST PQQKQ PQUKI PRINS Q9U 7X8 5PM DOA
DOI	10.3390/vaccines9030220
DatabaseName	PubMed CrossRef ProQuest Central (Corporate) Industrial and Applied Microbiology Abstracts (Microbiology A) ProQuest Central (purchase pre-March 2016) Technology Research Database ProQuest SciTech Collection ProQuest Natural Science Collection ProQuest Central (Alumni) (purchase pre-March 2016) Research Library (Alumni Edition) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection ProQuest Central ProQuest Natural Science Collection Environmental Sciences and Pollution Management ProQuest One Community College Coronavirus Research Database ProQuest Central Engineering Research Database ProQuest Central Student Research Library Prep SciTech Premium Collection (Proquest) (PQ_SDU_P3) Biological Sciences ProQuest research library Biological Science Database Research Library (Corporate) Biotechnology and BioEngineering Abstracts Publicly Available Content Database ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic MEDLINE - Academic PubMed Central (Full Participant titles) Directory of Open Access Journals
DatabaseTitle	PubMed CrossRef Publicly Available Content Database Research Library Prep ProQuest Central Student Technology Research Database ProQuest Central Essentials ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College Research Library (Alumni Edition) ProQuest Natural Science Collection ProQuest Central China Environmental Sciences and Pollution Management ProQuest Central Natural Science Collection ProQuest Central Korea Biological Science Collection ProQuest Research Library Industrial and Applied Microbiology Abstracts (Microbiology A) ProQuest Biological Science Collection ProQuest Central Basic ProQuest One Academic Eastern Edition Coronavirus Research Database Biological Science Database ProQuest SciTech Collection Biotechnology and BioEngineering Abstracts ProQuest One Academic UKI Edition Engineering Research Database ProQuest One Academic ProQuest Central (Alumni) MEDLINE - Academic
DatabaseTitleList	PubMed CrossRef Publicly Available Content Database
Database_xml	– sequence: 1 dbid: DOA name: Directory of Open Access Journals url: http://www.doaj.org/ sourceTypes: Open Website
DeliveryMethod	fulltext_linktorsrc
Discipline	Pharmacy, Therapeutics, & Pharmacology
EISSN	2076-393X
ExternalDocumentID	oai_doaj_org_article_c230c62d325f44bcbf59ff904d50f533 10_3390_vaccines9030220 33807516
Genre	Journal Article Review
GroupedDBID	3V. 53G 5VS 8FE 8FH 8G5 AADQD AAHBH ABUWG ADBBV AFKRA AFZYC ALMA_UNASSIGNED_HOLDINGS AOIJS AZQEC BBNVY BCNDV BENPR BHPHI BPHCQ CCPQU DIK DWQXO GNUQQ GROUPED_DOAJ GUQSH HCIFZ HYE IAO IHR KQ8 LK8 M2O M48 M7P MODMG M~E NPM OK1 PGMZT PIMPY PQQKQ PROAC RIG RNS RPM AAYXX CITATION 7T7 7XB 8FD 8FK C1K COVID FR3 MBDVC P64 PQEST PQUKI PRINS Q9U 7X8 5PM
ID	FETCH-LOGICAL-c487t-3ef90a1c362d432359f39145c4d3d4eb02d4fb17d452bf367f4067fa01d95df83
IEDL.DBID	RPM
ISSN	2076-393X
IngestDate	Tue Oct 22 15:12:56 EDT 2024 Tue Sep 17 21:20:54 EDT 2024 Fri Aug 16 22:25:53 EDT 2024 Sat Nov 09 16:39:08 EST 2024 Fri Nov 22 03:01:49 EST 2024 Wed Oct 16 00:43:35 EDT 2024
IsDoiOpenAccess	true
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	3
Keywords	trypanosomatids Chagas disease virus-like particles vaccine leishmaniasis African trypanosomiasis
Language	English
License	Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c487t-3ef90a1c362d432359f39145c4d3d4eb02d4fb17d452bf367f4067fa01d95df83
Notes	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1
ORCID	0000-0001-8504-9636 0000-0002-1000-0149 0000-0002-6948-9823 0000-0002-1811-7376 0000-0002-3100-0420
OpenAccessLink	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7998750/
PMID	33807516
PQID	2499311133
PQPubID	2032320
ParticipantIDs	doaj_primary_oai_doaj_org_article_c230c62d325f44bcbf59ff904d50f533 pubmedcentral_primary_oai_pubmedcentral_nih_gov_7998750 proquest_miscellaneous_2508576488 proquest_journals_2499311133 crossref_primary_10_3390_vaccines9030220 pubmed_primary_33807516
PublicationCentury	2000
PublicationDate	20210305
PublicationDateYYYYMMDD	2021-03-05
PublicationDate_xml	– month: 3 year: 2021 text: 20210305 day: 5
PublicationDecade	2020
PublicationPlace	Switzerland
PublicationPlace_xml	– name: Switzerland – name: Basel
PublicationTitle	Vaccines (Basel)
PublicationTitleAlternate	Vaccines (Basel)
PublicationYear	2021
Publisher	MDPI AG MDPI
Publisher_xml	– name: MDPI AG – name: MDPI
References	ref_50 Charpentier (ref_48) 2018; 34 Black (ref_38) 2016; 38 Ghorbani (ref_36) 2017; 12 Soares (ref_44) 2017; 168 Parthasarathy (ref_46) 2020; 11 Abaza (ref_43) 2019; 12 ref_52 Serradell (ref_71) 2019; 10 Rueda (ref_59) 2007; 178 Phan (ref_21) 2019; 37 Lee (ref_25) 2018; 36 Beaumier (ref_66) 2016; 34 Molina (ref_2) 2018; 391 ref_17 McLemore (ref_13) 2006; 10 ref_16 Pavanelli (ref_55) 2016; 10 Crisci (ref_6) 2012; 148 (ref_23) 2019; 37 Williams (ref_29) 2019; 9 Chichester (ref_27) 2018; 36 (ref_41) 2017; 2017 ref_60 Burza (ref_3) 2018; 392 Chroboczek (ref_5) 2014; 61 ref_24 ref_68 Metz (ref_19) 2018; 15 Karp (ref_37) 2017; 11 Chackerian (ref_53) 2007; 6 ref_22 ref_20 ref_63 Naskalska (ref_58) 2015; 64 Herrero (ref_15) 2008; 26 ref_26 Roy (ref_61) 2009; Volume 655 Jain (ref_64) 2015; 93 Hieu (ref_12) 2002; 20 (ref_49) 2019; 49 Paavonen (ref_14) 2007; 369 Jackson (ref_39) 2009; 27 Janitzek (ref_28) 2019; 9 Gomes (ref_7) 2017; 8 ref_31 Rios (ref_33) 2019; 200 ref_30 Zlotnick (ref_56) 2011; 19 Pijlman (ref_10) 2015; 10 Visciano (ref_57) 2011; 29 Metz (ref_18) 2016; Volume 1426 Rafati (ref_42) 2003; 4 Jeong (ref_62) 2017; 55 Oli (ref_32) 2020; 9 (ref_65) 2015; 2015 Frietze (ref_70) 2016; 18 Deml (ref_54) 2005; 42 Jackson (ref_40) 2016; 209 Yan (ref_69) 2015; 99 Bivona (ref_35) 2020; 1866 Dumonteil (ref_34) 2020; 38 Grgacic (ref_8) 2006; 40 ref_45 Brito (ref_67) 2011; 100 ref_1 Zeltins (ref_9) 2012; 53 Moura (ref_51) 2017; 3 Venters (ref_11) 2004; 3 Kennedy (ref_4) 2019; 266 Sarkar (ref_47) 2019; 55
References_xml	– volume: 9 start-page: 5260 year: 2019 ident: ref_28 article-title: A proof-of-concept study for the design of a VLP-based combinatorial HPV and placental malaria vaccine publication-title: Sci. Rep. doi: 10.1038/s41598-019-41522-5 contributor: fullname: Janitzek – ident: ref_26 doi: 10.3390/biomedicines8040091 – volume: 10 start-page: 559 year: 2006 ident: ref_13 article-title: Gardasil®: Introducing the New Human Papillomavirus Vaccine publication-title: Clin. J. Oncol. Nurs. doi: 10.1188/06.CJON.559-560 contributor: fullname: McLemore – ident: ref_31 doi: 10.3390/vaccines8010130 – volume: 200 start-page: 105168 year: 2019 ident: ref_33 article-title: Immunity and vaccine development efforts against Trypanosoma cruzi publication-title: Acta Trop. doi: 10.1016/j.actatropica.2019.105168 contributor: fullname: Rios – ident: ref_16 doi: 10.3390/vaccines8010139 – volume: 53 start-page: 92 year: 2012 ident: ref_9 article-title: Construction and Characterization of Virus-Like Particles: A Review publication-title: Mol. Biotechnol. doi: 10.1007/s12033-012-9598-4 contributor: fullname: Zeltins – volume: Volume 1426 start-page: 297 year: 2016 ident: ref_18 article-title: Production of Chikungunya Virus-Like Particles and Subunit Vaccines in Insect Cells publication-title: Chikungunya Virus: Methods and Protocols doi: 10.1007/978-1-4939-3618-2_27 contributor: fullname: Metz – volume: 6 start-page: 381 year: 2007 ident: ref_53 article-title: Virus-like particles: Flexible platforms for vaccine development publication-title: Expert Rev. Vaccines doi: 10.1586/14760584.6.3.381 contributor: fullname: Chackerian – volume: 178 start-page: 2361 year: 2007 ident: ref_59 article-title: Insect Baculoviruses Strongly Potentiate Adaptive Immune Responses by Inducing Type I IFN publication-title: J. Immunol. doi: 10.4049/jimmunol.178.4.2361 contributor: fullname: Rueda – volume: 20 start-page: 1803 year: 2002 ident: ref_12 article-title: Comparative efficacy, safety and immunogenicity of Hepavax-Gene and Engerix-B, recombinant hepatitis B vaccines, in infants born to HBsAg and HBeAg positive mothers in Vietnam: An assessment at 2 years publication-title: Vaccine doi: 10.1016/S0264-410X(01)00518-7 contributor: fullname: Hieu – volume: 19 start-page: 14 year: 2011 ident: ref_56 article-title: Virus assembly, allostery and antivirals publication-title: Trends Microbiol. doi: 10.1016/j.tim.2010.11.003 contributor: fullname: Zlotnick – ident: ref_68 – ident: ref_60 doi: 10.3390/v12030270 – volume: 12 start-page: 163 year: 2019 ident: ref_43 article-title: Expression of cysteine proteinases and cystatins in parasites and use of cysteine proteinase inhibitors in parasitic diseases. Part III: Protozoa (3): Kinetoplastids publication-title: Parasitol. United J. doi: 10.21608/puj.2019.20020.1055 contributor: fullname: Abaza – ident: ref_45 doi: 10.3390/pathogens8040178 – volume: 55 start-page: 220 year: 2017 ident: ref_62 article-title: Exploiting virus-like particles as innovative vaccines against emerging viral infections publication-title: J. Microbiol. doi: 10.1007/s12275-017-7058-3 contributor: fullname: Jeong – volume: 266 start-page: 2334 year: 2019 ident: ref_4 article-title: Update on human African trypanosomiasis (sleeping sickness) publication-title: J. Neurol. doi: 10.1007/s00415-019-09425-7 contributor: fullname: Kennedy – volume: 392 start-page: 951 year: 2018 ident: ref_3 article-title: Leishmaniasis publication-title: Lancet doi: 10.1016/S0140-6736(18)31204-2 contributor: fullname: Burza – volume: 61 start-page: 531 year: 2014 ident: ref_5 article-title: Virus-like particles as vaccine publication-title: Acta Biochim. Pol. doi: 10.18388/abp.2014_1875 contributor: fullname: Chroboczek – ident: ref_1 – volume: 93 start-page: 42 year: 2015 ident: ref_64 article-title: Formulation and stabilization of recombinant protein based virus-like particle vaccines publication-title: Adv. Drug Deliv. Rev. doi: 10.1016/j.addr.2014.10.023 contributor: fullname: Jain – volume: 37 start-page: 2925 year: 2019 ident: ref_21 article-title: Parainfluenza virus 5 (PIV5) amplifying virus-like particles expressing respiratory syncytial virus (RSV) antigens protect mice against RSV infection publication-title: Vaccine doi: 10.1016/j.vaccine.2019.04.042 contributor: fullname: Phan – volume: 34 start-page: 155 year: 2018 ident: ref_48 article-title: The Deadly Dance of B Cells with Trypanosomatids publication-title: Trends Parasitol. doi: 10.1016/j.pt.2017.10.001 contributor: fullname: Charpentier – volume: 42 start-page: 259 year: 2005 ident: ref_54 article-title: Recombinant HIV-1 Pr55gag virus-like particles: Potent stimulators of innate and acquired immune responses publication-title: Mol. Immunol. doi: 10.1016/j.molimm.2004.06.028 contributor: fullname: Deml – volume: 8 start-page: 226 year: 2017 ident: ref_7 article-title: Adjusted Particle Size Eliminates the Need of Linkage of Antigen and Adjuvants for Appropriated T Cell Responses in Virus-Like Particle-Based Vaccines publication-title: Front. Immunol. doi: 10.3389/fimmu.2017.00226 contributor: fullname: Gomes – ident: ref_52 doi: 10.1371/journal.pntd.0005951 – volume: 55 start-page: 327 year: 2019 ident: ref_47 article-title: Virus like particles-A recent advancement in vaccine development publication-title: Korean J. Microbiol. contributor: fullname: Sarkar – volume: 2015 start-page: 1 year: 2015 ident: ref_65 article-title: Experimental Vaccines against Chagas Disease: A Journey through History publication-title: J. Immunol. Res. – volume: 11 start-page: 21 year: 2017 ident: ref_37 article-title: Recent Advances in Vaccines Against Leishmania Based on Patent Applications publication-title: Recent Patents Biotechnol. contributor: fullname: Karp – volume: 49 start-page: 1082 year: 2019 ident: ref_49 article-title: Hypergammaglobulinemia sustains the development of regulatory responses during chronic Leishmania donovani infection in mice publication-title: Eur. J. Immunol. doi: 10.1002/eji.201847917 – ident: ref_30 – volume: 148 start-page: 211 year: 2012 ident: ref_6 article-title: Virus-like particles: The new frontier of vaccines for animal viral infections publication-title: Veter Immunol. Immunopathol. doi: 10.1016/j.vetimm.2012.04.026 contributor: fullname: Crisci – volume: 38 start-page: 735 year: 2016 ident: ref_38 article-title: Prospects for vaccination against pathogenic African trypanosomes publication-title: Parasite Immunol. doi: 10.1111/pim.12387 contributor: fullname: Black – ident: ref_24 – volume: 2017 start-page: 1 year: 2017 ident: ref_41 article-title: A Brief View of the Surface Membrane Proteins fromTrypanosoma cruzi publication-title: J. Parasitol. Res. – volume: 3 start-page: 119 year: 2004 ident: ref_11 article-title: Recombivax-HB: Perspectives past, present and future publication-title: Expert Rev. Vaccines doi: 10.1586/14760584.3.2.119 contributor: fullname: Venters – volume: 1866 start-page: 165658 year: 2020 ident: ref_35 article-title: Chagas disease vaccine design: The search for an efficient Trypanosoma cruzi immune-mediated control publication-title: Biochim. Biophys. Acta Mol. Basis Dis. doi: 10.1016/j.bbadis.2019.165658 contributor: fullname: Bivona – volume: 38 start-page: 4584 year: 2020 ident: ref_34 article-title: Safety and immunogenicity of a recombinant vaccine against Trypanosoma cruzi in Rhesus macaques publication-title: Vaccine doi: 10.1016/j.vaccine.2020.05.010 contributor: fullname: Dumonteil – volume: 40 start-page: 60 year: 2006 ident: ref_8 article-title: Virus-like particles: Passport to immune recognition publication-title: Methods doi: 10.1016/j.ymeth.2006.07.018 contributor: fullname: Grgacic – volume: 34 start-page: 2996 year: 2016 ident: ref_66 article-title: Status of vaccine research and development of vaccines for Chagas disease publication-title: Vaccine doi: 10.1016/j.vaccine.2016.03.074 contributor: fullname: Beaumier – volume: 369 start-page: 2161 year: 2007 ident: ref_14 article-title: Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: An interim analysis of a phase III double-blind, randomised controlled trial publication-title: Lancet doi: 10.1016/S0140-6736(07)60946-5 contributor: fullname: Paavonen – ident: ref_22 doi: 10.1371/journal.pntd.0005608 – volume: 10 start-page: 147 year: 2016 ident: ref_55 article-title: Citocinas e óxido nítrico na Doença de Chagas publication-title: Biosaúde contributor: fullname: Pavanelli – volume: 36 start-page: 5692 year: 2018 ident: ref_25 article-title: Virus-like particle vaccines expressing Toxoplasma gondii rhoptry protein 18 and microneme protein 8 provide enhanced protection publication-title: Vaccine doi: 10.1016/j.vaccine.2018.08.016 contributor: fullname: Lee – volume: 99 start-page: 10415 year: 2015 ident: ref_69 article-title: The application of virus-like particles as vaccines and biological vehicles publication-title: Appl. Microbiol. Biotechnol. doi: 10.1007/s00253-015-7000-8 contributor: fullname: Yan – volume: 11 start-page: 625 year: 2020 ident: ref_46 article-title: Defeating the trypanosomatid trio: Proteomics of the protozoan parasites causing neglected tropical diseases publication-title: RSC Med. Chem. doi: 10.1039/D0MD00122H contributor: fullname: Parthasarathy – volume: 26 start-page: 4795 year: 2008 ident: ref_15 article-title: Rationale and design of a community-based double-blind randomized clinical trial of an HPV 16 and 18 vaccine in Guanacaste, Costa Rica publication-title: Vaccine doi: 10.1016/j.vaccine.2008.07.002 contributor: fullname: Herrero – volume: 29 start-page: 4903 year: 2011 ident: ref_57 article-title: Generation of HIV-1 Virus-Like Particles expressing different HIV-1 glycoproteins publication-title: Vaccine doi: 10.1016/j.vaccine.2011.05.005 contributor: fullname: Visciano – volume: 4 start-page: 253 year: 2003 ident: ref_42 article-title: Leishmania Cysteine Proteinases: From Gene to Subunit Vaccine publication-title: Curr. Genom. doi: 10.2174/1389202033490439 contributor: fullname: Rafati – volume: Volume 655 start-page: 145 year: 2009 ident: ref_61 article-title: Virus-Like Particles as a Vaccine Delivery System: Myths and Facts publication-title: Advances in Experimental Medicine and Biology doi: 10.1007/978-1-4419-1132-2_11 contributor: fullname: Roy – volume: 37 start-page: 7256 year: 2019 ident: ref_23 article-title: Therapy with multi-epitope virus-like particles of B19 parvovirus reduce tumor growth and lung metastasis in an aggressive breast cancer mouse model publication-title: Vaccine doi: 10.1016/j.vaccine.2019.09.068 – ident: ref_50 doi: 10.1590/s1678-9946201759046 – volume: 15 start-page: 1 year: 2018 ident: ref_19 article-title: Dengue virus-like particles mimic the antigenic properties of the infectious dengue virus envelope publication-title: Virol. J. doi: 10.1186/s12985-018-0970-2 contributor: fullname: Metz – volume: 36 start-page: 5865 year: 2018 ident: ref_27 article-title: Safety and immunogenicity of a plant-produced Pfs25 virus-like particle as a transmission blocking vaccine against malaria: A Phase 1 dose-escalation study in healthy adults publication-title: Vaccine doi: 10.1016/j.vaccine.2018.08.033 contributor: fullname: Chichester – volume: 9 start-page: 13 year: 2020 ident: ref_32 article-title: Immunoinformatics and Vaccine Development: An Overview publication-title: ImmunoTargets Ther. doi: 10.2147/ITT.S241064 contributor: fullname: Oli – volume: 3 start-page: 1026 year: 2017 ident: ref_51 article-title: Virus-like Particle Display of the α-Gal Carbohydrate for Vaccination againstLeishmaniaInfection publication-title: ACS Cent. Sci. doi: 10.1021/acscentsci.7b00311 contributor: fullname: Moura – volume: 12 start-page: 25 year: 2017 ident: ref_36 article-title: Leishmaniasis in humans: Drug or vaccine therapy? publication-title: Drug Des. Dev. Ther. doi: 10.2147/DDDT.S146521 contributor: fullname: Ghorbani – ident: ref_63 doi: 10.3390/v12010035 – volume: 168 start-page: 326 year: 2017 ident: ref_44 article-title: In Vitro Inhibition of Leishmania Attachment to Sandfly Midguts and LL-5 Cells by Divalent Metal Chelators, Anti-gp63 and Phosphoglycans publication-title: Protist doi: 10.1016/j.protis.2017.03.004 contributor: fullname: Soares – volume: 10 start-page: 659 year: 2015 ident: ref_10 article-title: Enveloped virus-like particles as vaccines against pathogenic arboviruses publication-title: Biotechnol. J. doi: 10.1002/biot.201400427 contributor: fullname: Pijlman – volume: 18 start-page: 44 year: 2016 ident: ref_70 article-title: Engineering virus-like particles as vaccine platforms publication-title: Curr. Opin. Virol. doi: 10.1016/j.coviro.2016.03.001 contributor: fullname: Frietze – volume: 391 start-page: 82 year: 2018 ident: ref_2 article-title: Chagas disease publication-title: Lancet doi: 10.1016/S0140-6736(17)31612-4 contributor: fullname: Molina – volume: 209 start-page: 64 year: 2016 ident: ref_40 article-title: Gene family phylogeny and the evolution of parasite cell surfaces publication-title: Mol. Biochem. Parasitol. doi: 10.1016/j.molbiopara.2016.03.007 contributor: fullname: Jackson – volume: 10 start-page: 361 year: 2019 ident: ref_71 article-title: Efficient oral vaccination by bioengineering virus-like particles with protozoan surface proteins publication-title: Nat. Commun. doi: 10.1038/s41467-018-08265-9 contributor: fullname: Serradell – ident: ref_20 doi: 10.1371/journal.pone.0216533 – volume: 100 start-page: 34 year: 2011 ident: ref_67 article-title: COMMENTARY: Acceptable Levels of Endotoxin in Vaccine Formulations During Preclinical Research publication-title: J. Pharm. Sci. doi: 10.1002/jps.22267 contributor: fullname: Brito – volume: 64 start-page: 3 year: 2015 ident: ref_58 article-title: Virus like particles as immunogens and universal nanocarriers publication-title: Pol. J. Microbiol. doi: 10.33073/pjm-2015-001 contributor: fullname: Naskalska – volume: 9 start-page: 16833 year: 2019 ident: ref_29 article-title: Engineering a Virus-Like Particle as an Antigenic Platform for a Pfs47-Targeted Malaria Transmission-Blocking Vaccine publication-title: Sci. Rep. doi: 10.1038/s41598-019-53208-z contributor: fullname: Williams – volume: 27 start-page: 33 year: 2009 ident: ref_39 article-title: The Evolution of Amastin Surface Glycoproteins in Trypanosomatid Parasites publication-title: Mol. Biol. Evol. doi: 10.1093/molbev/msp214 contributor: fullname: Jackson – ident: ref_17 doi: 10.1128/JVI.01884-19
SSID	ssj0000913867
Score	2.263558
SecondaryResourceType	review_article
Snippet	Research on vaccines against trypanosomatids, a family of protozoa that cause neglected tropical diseases, such as Chagas disease, leishmaniasis, and sleeping...
SourceID	doaj pubmedcentral proquest crossref pubmed
SourceType	Open Website Open Access Repository Aggregation Database Index Database
StartPage	220
SubjectTerms	Adjuvants African trypanosomiasis Antigens Chagas disease Context COVID-19 Cytokines Development strategies Gene expression Human papillomavirus Immune system Immunostimulation Infections Infectious diseases Leishmaniasis Parasites Parasitic diseases Protozoa Review Tropical diseases trypanosomatids Tumor necrosis factor-TNF vaccine Vaccines Vector-borne diseases Viral infections Virulence Virus-like particles Viruses
SummonAdditionalLinks	– databaseName: Directory of Open Access Journals dbid: DOA link: http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LT9wwEB61nLhUbYGSliIjIcSBiMTPzZHlIQ5QrcQW9RY5diy4JIjsVtp_z0ySfSEkLkg52T6MZ-yZb-LxZ4BDjiHOYeiLvSmTWPJCx5mSLk4DYiTvuFGG7g5f35k__wYXl0STs3jqi2rCOnrgTnGnDjGy09wLroKUhSuCykLIEulVEhCrtN430SvJVOuDs1QMtOm4fATm9af_raOT6ibDVc3pde-VMNSy9b8FMV9XSq6Enquv8KXHjOysk_UbfCqr73A06kinZydsvLxD1ZywIzZa0lHPtuD2_mYUDzFYeXbfS8csfuxu-jihi1Ns-XudTWo2bmvD2fh5ho6ibmqCtJ5ddAc5zTb8vbocn1_H_SMKscNcZBKLEpVlU4eBykvBBWpPZKlUTnrhZVkk2ByK1HipeBGENgFDvAk2SX2mfBiIHdio6qrcBSalsgmxR1nEBNwqK42TVjsti0K44CM4nus0f-q4MnLMMUj9-Sv1RzAknS-GEcl124Cmz3vT5--ZPoK9ucXyfuc1OaaTmUAHTt0Hi27cM3QQYquynuIYRbz-Gn1XBD86Ay8kEcTAr1IdgVkz_Zqo6z3V40PLy20wdUUA9vMj5vYLNjlVz1C1m9qDjcnztPwNnxs_3W9X-gunCgR7 priority: 102 providerName: Directory of Open Access Journals
Title	VLP-Based Vaccines as a Suitable Technology to Target Trypanosomatid Diseases
URI	https://www.ncbi.nlm.nih.gov/pubmed/33807516 https://www.proquest.com/docview/2499311133 https://search.proquest.com/docview/2508576488 https://pubmed.ncbi.nlm.nih.gov/PMC7998750 https://doaj.org/article/c230c62d325f44bcbf59ff904d50f533
Volume	9
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
link	http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9wwEB66OfVS2qYPt2lQoIQe4qyth7U-5kkOSVnINvRm9LCahcYO693A_vuMZHsfoaeCT5YMY81I34w08wngO0WIMwh9sZVlEnOqszgX3MSpQx_JGiqF9LXDV7fy5-_R-YWnyRF9LUxI2jd6elz9fTiupvcht_LxwQz7PLHh-OZMYoyASDccwAB9w40QPSy_ecpGmWxpfBiG9MMnZfwhdZOjQVPq735jnmZd-DvON8AocPb_y9F8mS-5AUCXb-FN5zmSk1bCd_CqrN7D4bilnl4ekcm6kqo5IodkvCalXu7Czd31OD5FyLLkrhOUKHzI7WI69-VTZL3JTuY1mYQMcTKZLXG5qJvaO7aWnLfHOc0H-HV5MTm7irurFGKDEck8ZqXLE5UahCvLGWUidyxPuTDcMstLneBrp1NpuaDasUw6BHrpVJLaXFg3Yh9hp6qr8jMQzoVKPIeUQs-AKqG4NFxlJuNaM-NsBD_6MS0eW8aMAiMNr4nihSYiOPVjvurmqa7Di3r2p-gUXhgMkgyKzahwnGujHQqPf8OtSBw6qxHs9RoruvnXFBhU5gyXcd98sGrGmeOPQ1RV1gvsIzy7f4YrWASfWgWvJOkNJAK5pfotUbdb0FgDO3dnnF_--8uv8Jr6xBmf6Cb2YGc-W5TfYNDYxX7YMdgP9v4MFZkF-Q
link.rule.ids	230,315,729,782,786,866,887,2106,27933,27934,53800,53802
linkProvider	National Library of Medicine
linkToHtml	http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9swDCb6OGyXrnu13rpNA4Zih7qx9bDiY5_IsKQIUK_YzZAlawuw2kWcDMi_H-VHHsVOBXySZIAySZG0yI8AXyiaOI2mzzcyD3xOs8iPBdd-aNFHMppKIV3t8OBW3vzsX145mBzR1cLUSfs6m5wWf-5Pi8nvOrfy4V73ujyx3nh0ITFGQEvX24Zd1NcgWAvS6wM4Dlk_kg2QD8OgvvdXaXdNXcUo0pS67m_MAa0L1-V8zRzVqP3_czUfZ0yumaDrF08kfh_2Wp-TnDXTL2ErL17B8bgBrV6ckGRVg1WdkGMyXsFZL17D6G449s_R2Bly126QKHzI7Xwyc4VXZPV7nsxKktS55SSZLvCgKavSucSGXDYXQdUb-HF9lVwM_LYJg68xlpn5LLdxoEKNhs5wRpmILYtDLjQ3zPA8C3DYZqE0XNDMskhadBGkVUFoYmFsn72FnaIs8kMgnAsVOPQphT4FVUJxqbmKdMSzjGlrPPja8SJ9aLA2UoxRHAfTRxz04NzxarnMgWTXA-X0V9p-7VRjeKWRbEaF5TzTmUXicTfciMCim-vBUcfptNXcKsVwNGZoANz05-U06py7SFFFXs5xjXB9ASI8-zw4aARjSUknWB7IDZHZIHVzBiWlxvVuJePdk9_8BM8GyWiYDr_dfH8Pz6lLv3HpcuIIdmbTef4Btisz_1hryz_YaxqZ
linkToPdf	http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1La9wwEB7ygNJLmr4St2mrQgk9xLGth7U-JtksKU2CIdvQm5Elq11o7GW9W9h_35HtfYWeWvBJkkHyzOibsUbfAHyiCHEaoc83sgh9TvPYTwTXfmTRRzKaSiHd3eGrO3n7vde_dDQ5y1JfTdK-zken5a-H03L0s8mtHD_oYJEnFqQ3FxJjBES6YGxssA27aLMhXQvUm004iVgvli2ZD8PAPvittDuqrhNUa0pdBTjmyNaFq3S-BkkNc__f3M3HWZNrMDR49h8L2Ie9zvckZ-2Q57BVlC_gOG3Jq-cnZLi6i1WfkGOSrmit5y_h5v469c8R9Ay57xZJFD7kbjaaugtYZPWbnkwrMmxyzMlwMscNp6or5xob0m8PhOpX8G1wOby48rtiDL7GmGbqs8ImoYo0Ap7hjDKRWJZEXGhumOFFHmKzzSNpuKC5ZbG06CpIq8LIJMLYHnsNO2VVFodAOBcqdCxUCn0LqoTiUnMV65jnOdPWePB5IY9s3HJuZBirOClmj6TowbmT13KYI8tuGqrJj6z74pnGMEvjtBkVlvNc5xYnj6vhRoQW3V0PjhbSzjoLrjMMSxOGQOC6Py670fbcgYoqi2qGY4SrDxDjHujBQascy5kslMsDuaE2G1Pd7EFtafi9O-14889vfoAnaX-QXX-5_foWnlKXheOy5sQR7Ewns-IdbNdm9r4xmD-unR0Z
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=VLP-Based+Vaccines+as+a+Suitable+Technology+to+Target+Trypanosomatid+Diseases&rft.jtitle=Vaccines+%28Basel%29&rft.au=Queiroz%2C+Aline+Maria+Vasconcelos&rft.au=Oliveira%2C+Johny+Wysllas+de+Freitas&rft.au=Moreno%2C+Cl%C3%A1udia+Jassica&rft.au=Gu%C3%A9rin%2C+Diego+M+A&rft.date=2021-03-05&rft.issn=2076-393X&rft.eissn=2076-393X&rft.volume=9&rft.issue=3&rft_id=info:doi/10.3390%2Fvaccines9030220&rft.externalDBID=NO_FULL_TEXT
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2076-393X&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2076-393X&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2076-393X&client=summon